A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 8

Quantification of the ADCC activity of trastuzumab using iLite effector cells (V-variant) and ERBB2⁺ HEK293 targets: effect of incubation time. RTU iLite effector cells (1.2 × 10⁵ cells/well) and ERBB2⁺ HEK293 target cells were mixed at an E:T ratio of 4 : 1 and incubated for 4, 6, or 18 hours at 37°C in the presence of increasing concentrations of trastuzumab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as FL activity in RLU.